Literature DB >> 10327997

-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-.

C Olivier1, M Radal, S Mazaud, A P Jonville-Béra, C Martel, E Autret.   

Abstract

UNLABELLED: We report a rash after the first dose of antituberculosis polytherapy which raises questions concerning procedures to be followed. CASE REPORT: An 8-year-old child presented with a pruritic rash 1.5 hours after the first dose of isoniazide, rifampicine, pyrazinamide and ethambutol was simultaneously administered, which did not recur after successive re-administration of isoniazide and rifampicine. Pyrazinamide, which was re-administered last, induced a recurrence. Slower pyrazinamide re-administration allowed continuation of treatment.
CONCLUSION: A protocol for re-administration of the four drugs is suggested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10327997     DOI: 10.1016/s0929-693x(97)89371-2

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  3 in total

1.  Pyrazinamide-induced phototoxicity: a case report and review of literature.

Authors:  Subodh K Katiyar; Shailesh Bihari; Shivesh Prakash
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

2.  Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.

Authors:  Mario Sánchez-Borges; Bernard Thong; Miguel Blanca; Luis Felipe Chiaverini Ensina; Sandra González-Díaz; Paul A Greenberger; Edgardo Jares; Young-Koo Jee; Luciana Kase-Tanno; David Khan; Jung-Won Park; Werner Pichler; Antonino Romano; Maria José Torres Jaén
Journal:  World Allergy Organ J       Date:  2013-10-31       Impact factor: 4.084

3.  A case report. Rediscovering tuberculostatics drugs: skin rash and pyrazinamide.

Authors:  S Calpena Martínez; I Carrillo Acosta; B Álvarez Álvarez; M Górgolas Hernández-Mora
Journal:  Rev Esp Quimioter       Date:  2022-03-01       Impact factor: 2.515

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.